AMPH:NSD-Amphastar Pharmaceuticals, Inc (USD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | NSD

Last Closing Price

USD 18.03

Change

0.00 (0.00)%

Market Cap

USD 0.86B

Volume

0.23M

Average Target Price

USD 22.50 (+24.79%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; naloxone for opioid overdose; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; and Cortrosyn, a lyophilized powder use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; lidocaine jelly, a local anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection for newborn babies; atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate for emergency use in hospital settings; morphine injection; and lorazepam injection for surgery and medical procedures. In addition, it offers procainamide for documented ventricular arrhythmias; neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block, as well as recombinant human insulin API (active pharmaceutical ingredients) and porcine insulin API. Further, the company has a pipeline of 20 product candidates in various stages of development for various indications. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-26 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

N/A

USD7.45B 26.81 7.09
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.23B N/A N/A
PCRX Pacira BioSciences, Inc

N/A

USD2.52B 870.20 73.37
CRON Cronos Group Inc

N/A

USD1.77B 2.44 N/A
IRWD Ironwood Pharmaceuticals, Inc

N/A

USD1.51B 15.26 12.72
APHA Aphria Inc

N/A

USD1.22B 57.50 392.34
ATNX Athenex, Inc

N/A

USD1.14B N/A N/A
SUPN Supernus Pharmaceuticals, Inc

N/A

USD1.07B 9.18 5.84
PETQ PetIQ, Inc

N/A

USD0.91B 134.36 111.60
ENDP Endo International plc

N/A

USD0.75B N/A 8.11

ETFs Containing AMPH

Symbol Name Weight Mer Price(Change) Market Cap
PJP Invesco Dynamic Pharmaceu.. 0.00 % 0.56 %

N/A

USD0.36B
XSLV Invesco S&P SmallCap Low .. 0.00 % 0.25 %

N/A

USD1.61B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -6.53% 75% C 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.53% 75% C 51% F
Trailing 12 Months  
Capital Gain -10.83% 66% D 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.83% 66% D 42% F
Trailing 5 Years  
Capital Gain 64.36% 82% B- 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 64.36% 82% B- 71% C-
Average Annual (5 Year Horizon)  
Capital Gain 9.65% N/A N/A 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.65% N/A N/A 61% D-
Risk Return Profile  
Volatility (Standard Deviation) 20.82% N/A N/A 68% D+
Risk Adjusted Return 46.35% N/A N/A 68% D+
Market Capitalization 0.86B 85% B 68% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 224.88 13% F 6% F
Price/Book Ratio 2.15 60% D- 50% F
Price / Cash Flow Ratio 20.50 11% F 15% F
EV/EBITDA 27.46 38% F 26% F
Management Effectiveness  
Return on Equity 0.88% 88% B+ 55% F
Return on Invested Capital -3.39% 72% C- 38% F
Return on Assets 0.70% 80% B- 53% F
Debt to Equity Ratio 10.33% 61% D- 75% C
Technical Ratios  
Short Ratio 11.96 18% F 8% F
Short Percent 8.35% 46% F 26% F
Beta 0.99 68% D+ 59% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.